Quantum BioPharmaNASDAQ: QNTM

Profile

Sector:

Healthcare

Country:

Canada

IPO:

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$10.52 M
-99%vs. 3y high
18%vs. sector
-vs. 3y high
-vs. sector
-98%vs. 3y high
39%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Fri, 25 Oct 2024 13:30:00 GMT
$5.66-$0.03(-0.46%)

Dividend

No data over the past 3 years
$950.00 K$710.00 K

Analysts recommendations

Institutional Ownership

Included in screeners

No data

QNTM Latest News

Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
accesswire.com21 October 2024 Sentiment: NEGATIVE

Christian Attar Law Firm and Freedman Normand Friedland LLP, in conjunction with forensic investigators, have uncovered evidence of a potential multi-year market manipulation scheme that has caused substantial damages to the Company and its shareholders TORONTO, ON / ACCESSWIRE / October 21, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces the Company, on 20th October 2024, has filed a complaint in the United States District Court for the Southern District of New York alleging that CIBC World Markets (CIBC), RBC Dominion Securities (RBC), and others (the "Defendants") engaged in market manipulation schemes that violated Section 10(b) and Rule 10b-5(a) and (c) and Section 9(a) of the Securities Exchange Act of 1934.

What type of business is Quantum BioPharma?

Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.

What sector is Quantum BioPharma in?

Quantum BioPharma is in the Healthcare sector

What industry is Quantum BioPharma in?

Quantum BioPharma is in the Drug Manufacturers - Specialty & Generic industry

What country is Quantum BioPharma from?

Quantum BioPharma is headquartered in Canada

What is Quantum BioPharma website?

https://www.fsdpharma.com

Is Quantum BioPharma in the S&P 500?

No, Quantum BioPharma is not included in the S&P 500 index

Is Quantum BioPharma in the NASDAQ 100?

No, Quantum BioPharma is not included in the NASDAQ 100 index

Is Quantum BioPharma in the Dow Jones?

No, Quantum BioPharma is not included in the Dow Jones index

When was Quantum BioPharma the previous earnings report?

No data

When does Quantum BioPharma earnings report?

The next expected earnings date for Quantum BioPharma is 14 November 2024